News Breaks |
|
|
| October 24, 2012 |
| 06:25 EDT |  | AMRN, AZN, MRK, LLY, ABT, PFE | AstraZeneca may launch cash bid for Amarin, Daily Mail reports
According to the Daily Mail, AstraZeneca (AZN) may be planning to launch a cash bid for Amarin (AMRN). The Mail says other larger pharmaceutical companies, like Merck (MRK), Eli Lilly (LLY), Abbott (ABT) and Pfizer (PFE), "would love to get their hands" on Amarin for Vascepa. Reference Link |
|
|
News For AMRN;AZN;MRK;LLY;ABT;PFE From The Last 14 Days Check below for free stories on AMRN;AZN;MRK;LLY;ABT;PFE the last two weeks. |
|
|
| May 21, 2013 |
| 17:03 EDT |  | MRK | Merck announces $5B share repurchase
 Subscribe for More Information |
|
| 17:01 EDT | | MRK | Merck announces $5B accelerated share repurchase
Subscribe for More Information |
|
| 11:41 EDT |  | AMRN | Options with decreasing implied volatility: SGMO WCRX NTI TSLA AMRN
|
|
| 09:29 EDT | | AZN | AstraZeneca says Phase III studies of Naloxegol met primary, secondary endpoints
AstraZeneca (AZN) presented the results of two pivotal Phase III studies of naloxegol showing the 25 mg dose of the investigational drug met its primary and secondary endpoints for efficacy and showed a safety profile consistent with previous studies. Data was presented at the Digestive Disease Week meeting in Orlando, Florida. The primary endpoint in both trials was percentage of OIC responders, versus placebo, over 12 weeks of treatment. The secondary endpoints included the 12-week response rate in a laxative inadequate response population, the median time to first spontaneous bowel movement and the number of days per-week with at least one bowel movement. Plans for naloxegol will be finalized over the coming months, incorporating the outcome of ongoing discussions with health authorities in the US, EU and Canada, the company said. Naloxegol, a peripherally-acting mu-opioid receptor antagonist, has been specifically designed for the treatment of opioid-induced constipation and is part of the exclusive worldwide license agreement announced on 21 September 2009, between AstraZeneca and Nektar Therapeutics (NKTR). |
|
| 08:03 EDT | | ABT | Abbott announces CE Mark for coronary drug eluting stent
Subscribe for More Information |
|
| 07:44 EDT |  | MRK | Sachs Associates to host a forum
Subscribe for More Information |
|
| 07:24 EDT | | LLY | Global Health Care to host a conference
Subscribe for More Information |
|
| 07:16 EDT | | PFE | Pfizer management to meet with Leerink
Subscribe for More Information |
|
| May 20, 2013 |
| 17:49 EDT | | MRK | Merck sleep drug effective, dosages questioned, WSJ reports
Subscribe for More Information |
|
| 17:04 EDT | | PFE | Pfizer discontinues phase 3 study of inotuzumab ozogamicin
Subscribe for More Information |
| |
| 10:11 EDT |  | ABT | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 07:32 EDT | | MRK | Society for Information Display / IHS to host a conference
Display Week 2013 is being held in Vancouver, British Columbia on May 19-24. |
|
| 06:01 EDT | | ABT | Abbott upgraded to Buy from Neutral at Goldman
Goldman upgraded Abbott to reflect accelerating growth driven by emerging markets, better growth and product mix, new product launches, and market share gains. Price target raised to $44 from $38. |
|
| May 17, 2013 |
| 14:12 EDT | | AMRN | Amarin shares slip after FDA updates Orange Book
Subscribe for More Information |
|
| 10:36 EDT | | AZN | Leerink's major/specialty pharma analyst holds analyst/Industry conference call
Subscribe for More Information |
|
| 08:41 EDT | | AZN | Impax commenced shipment of authorized generic Zomig
Impax (IPXL) announced that its generics division, Global Pharmaceuticals, commenced shipment of authorized generic Zomig tablets, as part of an agreement with AstraZeneca (AZN). Zomig is indicated for the treatment of migraine headaches in adults. According to IMS Health data, U.S. sales of Zomig tablets and orally disintegrating tablets were approximately $196M in the 12 months ended April 2013. |
|
| May 16, 2013 |
| 08:55 EDT | | MRK, PFE, LLY | BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call
Subscribe for More Information |
|
| May 15, 2013 |
| 11:04 EDT | | AMRN | Amarin management to meet with Lazard Capital
Meeting to be held in the Mid-Atlantic area on May 16 hosted by Lazard Capital. |
|
| May 14, 2013 |
| 17:39 EDT | | MRK | Moody's lowers Merck's guaranteed debt to A1 from Aa3; stable outlook
Moody's Investors Service lowered the long-term ratings of Merck by one notch, including the guaranteed senior unsecured rating to A1 from Aa3 and the non-guaranteed senior unsecured rating to A2 from A1. This action concludes a review for downgrade initiated on May 1, 2013. At the same time, Moody's affirmed Merck's Prime-1 commercial paper rating. The rating outlook is stable. |
|
| 09:09 EDT | | LLY | Eli Lilly announces CEO John Lechleiter recovering from surgery
Subscribe for More Information |
| |
|
|
|
|
